Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed this Form 8-K to report the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following proposals were approved by stockholders at the Annual Meeting:
- Election of Directors: Three Class III directors were elected to three-year terms expiring at the 2029 Annual Meeting: Krishna Vaddi, Paul Scherer, and Katina Dorton. All nominees received significant majority support, with "For" votes ranging from approximately 25.5 million to 27.0 million shares.
- Appointment of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 31,841,080 "For" votes against 4,951 "Against" votes.
- Executive Compensation (Say-on-Pay): The advisory vote to approve 2025 compensation for named executive officers was approved with 26,869,142 "For" votes.
- Compensation Vote Frequency: Stockholders voted to hold advisory votes on executive compensation annually (1 Year), with 26,877,941 shares voting for this frequency.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Krishna Vaddi, Paul Scherer, Katina Dorton) which extends through the 2029 Annual Meeting.
- Confirm the ratification of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2026.
- Note that the company has established an annual frequency for future advisory votes on executive compensation.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.